apixaban (Eliquis)

Bristol-Myers Squibb · F10 · Small Molecule

Status

✓ Approved

Indications

5 conditions

Clinical Trials

328 total

Active Trials

98 ongoing

Targets

F10

What is apixaban?

Last updated: February 2025

apixaban is a small molecule developed by Bristol-Myers Squibb. It is approved for therapeutic indications via oral (po).

apixaban acts on 1 molecular target:

F10	coagulation factor X (FXA, FX)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

There are currently 328 clinical trials registered, with 98 actively ongoing.

Trial ID	Phase	Title	Status
NCT07404345	Phase 4	Efficacy of Low-Dose Apixaban Added to Standard Heparin Lock to Prevent Dysfunction of Tunneled Hemo	● Not Yet Recruiting
NCT06953726	Phase 4	CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual	● Not Yet Recruiting
NCT04809818	Phase 1	Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, an	Completed
NCT07175428	Phase 2	A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REG	● Recruiting
NCT07005024	Phase 3	A Comparison of Anticoagulant Dosing Strategies to Reduce VTE and Mortality in Cancer Outpatients: A	● Recruiting
NCT07015905	Phase 3	A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Facto	● Recruiting

+324 more trials available with free account

Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.

apixaban is developed for 5 unique indications across 4 therapeutic areas.

Therapeutic Area	Condition	Phase
Vascular disorders	Venous thrombosis	✓ Approved
Respiratory, thoracic and mediastinal disorders	Pulmonary thrombosis	✓ Approved
Vascular disorders	Thrombosis	✓ Approved
Nervous system disorders	Delayed ischaemic neurological deficit	✓ Approved
Cardiac disorders	Acute coronary syndrome	Phase III